Published in final edited form as:

J Mol Cell Cardiol. 2009 December ; 47(6): 752–760. doi:10.1016/j.yjmcc.2009.07.025.

Mechanistic Insights into Folic Acid-dependent Vascular Protection: Dihydrofolate reductase-mediated Reduction in Oxidant Stress in Endothelial Cells and Angiotensin II-Infused Mice:

A Novel HPLC-based Fluorescent Assay for DHFR Activity

Ling Gao, MD, PhD, Karel Chalupsky, PhD, Enrico Stefani, and Hua Cai, MD, PhD

Division of Molecular Medicine, Cardiovascular Research Laboratories, Departments of Anesthesiology and Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA

Abstract

Background—Folate supplementation improves endothelial function in patients with hyperhomocysteinemia. Mechanistic insights into potential benefits of folate on vascular function in general population however, remain mysterious.

Methods and Results—Expression of dihydrofolate reductase (DHFR) was markedly increased by folic acid (FA, 50 μ mol/L, 24 hr) treatment in endothelial cells. Tetrahydrofolate (THF) is formed after incubation of purified DHFR or cellular extracts with 50 μ mol/L of substrate dihydrofolic acid. THF could then be detected and quantified by high performance liquid chromatography (HPLC) with a fluorescent detector (295/365 nm). Using this novel and sensitive assay, we found that DHFR activity was significantly increased by FA. Furthermore, FA improved redox status of Ang II treated cells by increasing H₄B and NO[•] bioavailability while decreasing superoxide (O₂^{•−}) production. It however failed to restore NO[•] levels in DHFR siRNA-transfected or methotrexate pre-treated cells, implicating a specific and intermediate role of DHFR. In mice orally administrated with FA (15 mg/kg/day, 16 days), endothelium upregulation of DHFR expression and activity occurred in correspondence to improved NO[•] and H₄B bioavailability, and this was highly effective in reducing Ang II infusion (0.7 mg/kg/day, 14 days)-stimulated aortic O₂^{•−} production. 5'-methyltetrahydrofolate (5'-MTHF levels, GTPCH1 expression and activity remained unchanged in response to FA or Ang II treatment *in vitro* and *in vivo*.

Conclusions—FA supplementation improves endothelial NO[•] bioavailability via upregulation of DHFR expression and activity, and protects endothelial cells from Ang II-provoked oxidant stress both *in vitro* and *in vivo*. These observations likely represent a novel mechanism (intermediate role of DHFR) whereby FA induces vascular protection.

© 2009 Elsevier Ltd. All rights reserved.

Address Correspondence to: Hua Linda Cai, M.D., Ph.D., Division of Molecular Medicine, Cardiovascular Research Laboratories (CVRL), The Departments of Anesthesiology and Medicine, UCLA David Geffen School of Medicine, 650 Charles E Young Drive, BH550 Los Angeles, CA, 90095, Tel: 310-267-2303, Fax: 310-825-0132, hcai@mednet.ucla.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

DISCLOSURE

None.

Keywords

Folic acid (FA); dihydrofolate reductase (DHFR); endothelial nitric oxide synthase (eNOS); nitric oxide (NO[•]); angiotensin II (Ang II); Tetrahydrofolic acid (THF)

INTRODUCTION

The most widely known therapeutic function of folic acid (FA) is to prevent birth defect (primarily neural tube defects), based on its role in neonatal development [1,2]. Its other major therapeutic function is to treat patients with hyperhomocysteinemia [3]. FA is required for the remethylation of homocysteine to form methionine, thus reducing the homocysteine level in the plasma. Oral supplementation of FA effectively decreases plasma homocysteine levels [3]. Both hyperhomocysteinemia and hyperhomocysteinuria have been shown to be independent risk factors for atherosclerotic vascular diseases [4–10]. One of the molecular mechanisms responsible for hyperhomocysteinemia-induced disease is increased production of reactive oxygen species and consequent endothelial dysfunction [11,12]. It is however unclear whether FA, besides reducing homocysteine levels metabolically, modulates endothelial function directly in subjects with or without hyperhomocysteinemia. It is also unclear whether FA treatment of hyperhomocysteinemic patients is beneficial in disease progression and prognosis.

As a FDA-approved agent, FA or combined vitamin therapy has been investigated for its role in cardiovascular therapeutics in various clinical conditions, and the outcomes (myocardial infarction, stroke, thromboembolic events and mortality) have remained controversial [5,13–15]. However, it is worth noting that the larger trials (i.e. HOST [14], VISP [16], HOPE-2 [17]) were conducted in subjects with advanced atherosclerotic vascular diseases where disease regression might be more difficult. Even though, a significant reduction was observed in stroke morbidity with FA treatment after removal of the HOST trial [14,18] (subjects with renal failure) based on meta-analysis [5,19–21]. Therefore, FA supplementation can potentially benefit patients with vascular diseases, although the role of homocysteine during the course of interventions is unclear [22]. More interestingly, FA supplementation was demonstrated to improve endothelial function in subjects without elevated homocysteine levels, indicating an independent effect [22]. Whether this is attributed to direct nitric oxide (NO[•]) production and/or reduced oxidant stress, as well as the potential underlying mechanisms, remains to be fully elucidated.

Accumulating evidence has established that a deficiency in endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (H₄B) causes eNOS to produce superoxide (O₂^{•-}) rather than NO[•], resulting in eNOS uncoupling and increased oxidant stress [23,24]. This change in eNOS enzymatic function is independent of gene regulation. Under pathological conditions such as diabetes and ischemic renal dysfunction where angiotensin II (Ang II) levels are elevated [23], we and others have shown that a deficiency in H₄B salvage enzyme dihydrofolate reductase (DHFR) is responsible for reduced H₄B and NO[•] bioavailability [23,25–27]. Therefore in the present study we examined FA regulation of DHFR protein expression and activity, and DHFR-mediated changes in NO[•] and O₂^{•-} productions in cultured endothelial cells and Ang II-infused mice.

A sensitive HPLC-based activity assay for DHFR was first established. Endothelial cells were exposed to Ang II in the presence or absence of FA, followed by detection of NO[•] and O₂^{•-} production specifically and quantitatively using electron spin resonance (ESR). Basal FA regulation of DHFR expression and activity were also analyzed. In Ang II-infused mice, oral administration of FA was examined for its effects on aortic productions of NO[•] and O₂^{•-}

Overall FA potentially improved NO[•] bioavailability, intracellular H₄B content while reducing oxidant stress both *in vitro* and *in vivo*. These responses were found dependent on an upregulation in DHFR. These data demonstrate an innovative mechanism whereby FA may protect against cardiovascular disorders in a general population.

MATERIALS AND METHODS

Materials

Monoclonal antibodies for DHFR and eNOS were purchased from Research Diagnostics (Flanders, NJ) and BD Transduction Laboratories (San Jose, CA) respectively. Tetrahydrofolate, FA, dihydrofolic acid, recombinant DHFR, NADPH and all other reagents were purchased from Sigma-Aldrich in highest purity (St. Louis, USA).

Cell Culture, Cell Treatments and NO[•] Detection

Bovine aortic endothelial cells (BAECs, Cell Systems, Kirkland, WA) were grown in media 199 containing 10% fetal bovine serum (FBS) until confluence, and quiescent with 5% FBS media. Confluent cells were exposed to FA (50 µmol/L) or Ang II (100 nmol/L) or combination of these two for 24 hr, then rinsed with modified Krebs's/HEPES buffer, incubated with freshly prepared NO[•]-specific spin trap Fe²⁺(DETC)₂ colloid (0.5 mmol/L) for 60 min. Gently collected suspensions of cells were snap-frozen in liquid nitrogen and loaded into a finger Dewar for analysis with an eScan ESR spectrophotometer (Bruker) at the following settings: center field, 3410; field sweep, 100 G; microwave frequency, 9.76 GHz; microwave power, 13.26 mW; modulation amplitude, 9.82 G; 10240 points of resolution; and receiver gain, 356. The aortic NO[•] production was measured as previously described [25].

Immunoblot Analysis

Cells were lysed with lysis buffer (0.2 mol/L Tris, 1.5 mol/L NaCl, 10 mmol/L EDTA, 10 mmol/L EGTA, 25 mmol/L sodium pyrophosphate, 10 mmol/L β-glycerophosphate, 10 mmol/L Na₃VO₄, 1 mmol/L PMSF, 2 µmol/L leupeptin and 10% Triton, pH 7.4) for 1hr. The samples were then prepared for Western analysis. Forty µg of protein was separated by 10% SDS PAGE, transferred to nitrocellulose membranes, and probed with DHFR (1:1000) or eNOS (1:1000) antibody following standard immunoblotting procedure.

HPLC-based H₄B Measurement

Endothelial cells were lysed using trichloroacetic acid containing 10 mmol/L DTT. Lysates were subjected to differential oxidation in acidic (0.2 mol/L trichloroacetic acid containing 2.5% I₂/10% KI) or alkalytic (0.1 mol/L NaOH containing 0.9% I₂/1.8% KI) solutions as briefly described previously [25]. After centrifugation, 20 µl of supernatant was injected into a HPLC system. Excitation and emission wavelengths of 350 nm and 450 nm were used to detect fluorescent H₄B and its oxidized species.

Determination of GTPCH1 mRNA expression

Cellular GTPCH1 mRNA was extracted using RNeasy kit from Qiagen (Huntsville, AL) according to manufacturer instruction. The cDNA was synthesized with script III from Invitrogen (Carlsbad CA) and Real-time PCR was performed on a Bio-Rad iCYCLER iQ real-time PCR machine as previously described [28].

Detection of GTPCH1 activity

Aortic segments were powdered under liquid nitrogen using mortar and pestle. To access GTPCH1 activity, tissue powders or cell pellets were lysed and incubated with GTP (0.75 mmol/L final concentration) at 37°C for 90 min in the dark. The reaction product was oxidized

to neopterin triphosphate by acidic iodine (1% I₂ and 2% KI in 2 mol/L TCA). After reduction of excessive iodine by ascorbic acid (2%) and adjustment of pH to 7.0, reaction products were monitored by HPLC with fluorescent detection (365/446 nm). The detailed chromatographic procedure has been described elsewhere [29].

Determination of 5'-MTHF levels

Tissue powders or cell pellets were dissolved/re-suspended in ascorbic acid (57 mmol/L) solution. Samples were repeatedly frozen and thawed or sonicated to break cell membranes and then vortexed and incubated at 37°C for 60 min. Samples were diluted with buffer solution (0.2 mol/L potassium phosphate dibasic and 30 mmol/L mercaptoethanol, pH 8.5) and heated at 100°C for 10 min. After being vortexed for 30 sec and centrifuged at 10,000 g for 15 min, the supernatants were collected and analyzed using HPLC as previously described [30]. Briefly, the 5'-MTHF signals were monitored by fluorescent detection (295/360 nm) under the mobile phase of methanol:0.6% acetic acid in water (14:86, v/v) at a flow-rate of 1 ml/min. The quantitative levels of 5'-MTHF were calculated based on a calibration curve established using known concentrations of 5'-MTHF going through the same preparation and detection procedures.

Oral Administration of FA in Ang II-infused Mice

The C57BL/6 mice from Jackson Laboratories (6–9 weeks old, total 64) were separated into four groups. Two were put on standard mice chow (Harlan) and two on FA rich (15 mg/kg/day) chow. On average, mice weighed 25 g and consumed 3.5 g of diet daily. To prepare FA rich chow, standard mouse chow was grounded, mixed well with FA, and food tablets produced by a customized press machine. All mice were fed ad libitum and tablets with FA were replaced every two days. Half of mice on each diet were then anesthetized and osmotic pumps (Durect corporation) containing angiotensin II (0.7 mg/kg/day, Sigma) were implanted subcutaneously after anesthetization. Two weeks later mice aortas were isolated and sectioned. Sections from well-defined regions, 1 mm below subclavian artery, were used for ESR analysis of O₂^{•-} production. The rest of the aorta was used for ESR measurement of NO[•] and western analysis of eNOS and DHFR expression. The procedures were carried out based on protocols approved by the UCLA Institutional Animal Care and Use Committee (IACUC).

ESR Detection of Aortic Superoxide Production

As previously described [25], aortic segments (~3 mm) were mixed with freshly prepared spin trap (CMH, 0.5 mmol/L) in the presence or absence of 100 units/ml polyethylene glycol-conjugated superoxide dismutase (PEG-SOD), and loaded to glass capillaries for immediate kinetic analysis of O₂^{•-} production. The ESR settings were as the followings: biofield, 3494.50; field sweep, 9 G; microwave frequency, 9.75 GHz; microwave power, 21.02 mW; modulation amplitude, 2.47 G; 4,096 points of resolution; receiver gain, 1000; and kinetic time, 10 min. The PEG-SOD inhibitable O₂^{•-} signals at 10 min time point, normalized by protein concentrations, were compared among different experimental groups.

EC-Washout and Western Blotting

To determine changes in DHFR expression and activity in the mouse endothelium, an additional group of 32 mice were studied as described above. Upon harvest, whole aorta was cut open longitudinally and digested with collagenase (0.6 mg/ml) for 20 min at 37°C. The supernatant was centrifuged and the endothelial cells were collected from the pellet. Cells were lysed and forty µg of protein separated by 10% SDS/PAGE, transferred to nitrocellulose membranes, and probed with DHFR (1:250) or eNOS (1:1,000) antibody respectively. The endothelium-denuded vessels were also homogenated and subjected to Western analysis of eNOS and DHFR following identical procedure.

Statistics

Data are presented as Means $\pm$ SEM from independent experiments. Differences between control and treatment groups were compared by ANOVA and considered significant when $p < 0.05$.

RESULTS

Folic Acid Upregulates Endothelial DHFR Expression and NO[•] Production

Post confluent bovine aortic endothelial cells were treated with folic acid (FA, 50 μ mol/L, 24 hr) prior to Western analysis of DHFR and eNOS protein expressions. As shown by represent blot and grouped densitometric data, FA supplementation resulted in a significant upregulation of DHFR while not affecting eNOS expression (Figs. 1A and 1B). Of note, endothelial cell production of NO[•] was also increased (Figs. 1C and 1D).

Establishment of a Novel HPLC-based Assay for DHFR Activity

In order to determine specifically DHFR activity from cells, a sensitive HPLC-based assay was established. Purified recombinant DHFR or cell lysates were incubated with dihydrofolate (50 μ mol/L) and NADPH (200 μ mol/L) for 20 min at 37°C, in a 0.1 mol/L potassium phosphate assay buffer (pH 7.4) containing 1 mmol/L DTT, 0.5 mmol/L KCl, 1 mmol/L EDTA and 20 mmol/L sodium ascorbate. At the end of the incubation, the reaction was terminated by addition of 0.2 mol/L trichloroacetic acid, and then product was stabilized by addition of stabilization solution (200 mg of sodium ascorbate and 30 mg of DTT in 1 ml of water, 1:10 dilution for the final working solution).

The product, tetrahydrofolate/tetrahydrofolic acid (THF), was measured using a Shimadzu HPLC system consisted of C-18 column (250- 4.6-mm C18 column Alltech, Deerfield) and fluorescent detector, at wavelengths of 295 nm for excitation and 365 nm for emission. The mobile phase was isocratic flow 1 ml/min of mixture of 7% acetonitrile with 5 mmol/L KH₂PO₄; pH 2.3. The retention time of tetrahydrofolic acid was at about 7.5 minute. The specific THF peaks, under different assay conditions, were highlighted in dotted frame in Fig. 2 tracing F. In Fig. 2, tracing A shows a standard peak of THF (50 nmol/L) in assay buffer. Tracing B represents the reaction containing only substrate dihydrofolic acid, indicating that THF peak was unique, without overlapping with the dihydrofolic acid peak. Tracing C & E demonstrate that when NADPH or substrate was missing from the reaction, no THF was produced. Tracing D indicates that an inactive enzyme (boiled to inactivate) also failed to generate a specific THF peak. Only tracing F shows a characteristic THF peak when recombinant enzyme was mixed with proper concentrations of dihydrofolic acid and NADPH in the right assay buffer. The constituents of each tracing are shown on the right panel of Fig. 2. The THF content was calculated against a standard curve prepared by using THF solutions in assay buffer. Data are presented as nmol production of THF.

Optimization of the DHFR Activity Assay

As shown in Fig. 3A, THF formation was linearly correlated with time within 20 min incubation. A dose-dependent effect of electron donor NADPH (maximized at $>200 \mu$ mol/L) on THF formation was observed (Fig. 3B). In addition, formation of THF was linearly correlated with protein content either recombinant protein or BAEC lysates (Figs. 3C&D). Using purified DHFR and dihydrofolic acid as the substrate, formation of THF at different pH was compared and pH 7.4–7.5 was found to be the optimal for the reaction (Fig. 3E). The K_m of the enzyme was calculated to be $4.5 \pm 0.8 \mu$ mol/L and the V_{max} for the enzyme to be 999.7 ± 74.2 nmol/min/ μ g protein (Fig. 3F). Folic acid, when serving as a much weaker substrate,

showed a K_m of $28.8 \pm 5.3 \mu\text{mol/L}$ and the V_{max} for the enzyme is $2.5 \pm 0.2 \text{ nmol/min}/\mu\text{g}$ protein.

Validation of the DHFR Activity Assay

The validation parameters were specificity, linearity, extraction recovery, precision and accuracy. Blank cell lysates and pure tetrahydrofolate were screened to determine the specificity (see Fig. 2). Linearity was tested on three different sets of calibration curves. The lowest concentration of the linear regression defined the lower limit of qualification (LLOQ). The LLOQ for tetrahydrobiopterin was 25 nmol/L at a signal-to-noise (S/N) ratio of 5 (highest sensitivity, $\times 16$ gain for HPLC setting).

The extraction recovery of tetrahydrofolate was assessed at different concentrations of tetrahydrofolate, and calculated by comparing the peak area of tetrahydrofolate in assay buffer containing cell lysates to the peak area obtained with the same concentration of tetrahydrofolate in assay buffer. The mean recovery rate of tetrahydrobiopterin at low, middle and high concentrations ($30, 50, 75 \text{ nmol/L}$) was greater than 95% (Table 1). The mean regression equation weighed by concentration (nM) was $y = (331400 \pm 15010)x - (1126000 \pm 853400)$ ($r^2=0.9959$).

Intra-day assay accuracy and precision of quality controls were measured using three determinations per concentration at the same day. Inter-day assay accuracy and precision of quality control were measured using three determinations per concentration on three consecutive days. The data of accuracy and precision are represented by relative standard deviation (R.S.D.) and relative error (RE) as shown in Table 2.

Folic Acid Improves Endothelial Nitric Oxide Bioavailability via DHFR

As shown in Figure 4A, Ang II decreased DHFR expression in endothelial cells which is consistent with our previous findings [23]. FA supplementation not only increased DHFR expression but also preserved DHFR expression from being attenuated by Ang II (Fig. 4A). Similarly, DHFR activity was downregulated by Ang II but upregulated/restored by FA (Fig. 4B). The upregulation in DHFR expression and activity may increase H_4B level via augmented salvation of H_2B . Indeed, the ratio of oxidized H_4B (H_2B and other intermediates) over total pterins was decreased in FA treated cells. Moreover, FA treatment prevented H_4B from being oxidized by Ang II (Figs. 4C and 4D). Meanwhile, bioavailable NO^* was decreased by Ang II treatment, but markedly improved by FA pre-treatment (Fig. 4E).

In additional experiments, endothelial cells were transfected with control and DHFR siRNA prior to FA stimulation. As shown in Fig. 5A, DHFR siRNA efficiently attenuated DHFR protein expression. Although FA increased NO^* production in control siRNA transfected cells, it failed to provoke any changes in NO^* level in DHFR siRNA transfected cells, indicating a specific and intermediate role of DHFR in FA induced augmentation of NO^* production (Fig. 5B). Moreover, pre-inhibition of DHFR with methotrexate ($1 \mu\text{mol/L}$) also attenuated the beneficial effects of FA on endothelial NO^* bioavailability following Ang II stimulation (Fig. 5C). GTPCH1, the rate limiting enzyme for H_4B *de novo* synthetic pathway were also examined for its expression and activity to further determine whether DHFR has an independent role in regulating H_4B availability. As shown in Fig. 5D and 5E, both GTPCH1 mRNA level and activity were not changed by FA treatment. 5'-methyltetrahydrofolate (5'-MTHF), a bioactive form of FA which may have similar benefits on eNOS function [31], also remained unchanged with FA treatment.

Folic Acid Increases NO[•] Bioavailability While Reducing O₂^{•-} Production in Angiotensin II-infused Mice-Role of DHFR

To examine whether FA would exert beneficial effects on vascular endothelial function *in vivo*, control or Ang II infused mice were on FA-rich diet for 2 weeks. Aortas were then harvested and a 2 mm section of descending aorta was subjected to O₂^{•-} detection immediately using ESR. As shown by representative kinetic curves, and quantitative data for O₂^{•-} production at the end of 10 min, Ang II-dependent O₂^{•-} was completely attenuated by FA treatment (Figs. 6A&B). After O₂^{•-} measurement, the rest of the aortas were subjected to NO[•] detection by ESR. FA alone increased NO[•] production by 40% in control mice (Figs. 6C&D). Whereas aortic NO[•] production was markedly reduced by Ang II infusion, it was restored to near control level by oral administration with FA (Figs. 6C&D).

In additional experiments, DHFR expression was examined using intact or endothelium-denuded aortas. Of note, eNOS was completely absent in the denuded vessels (Fig. 7A) whereas its expression was abundant in the endothelial cells but downregulated by Ang II (Fig. 7A). Oral administration of FA significantly improved endothelial DHFR expression in untreated control mice, as shown by both representative blots and quantitative data (Figs. 7B&C), which is similar to what is observed *in vitro* (Fig. 1). In Ang II infused animals, endothelial DHFR expression was diminished, which was however significantly restored by FA administration (Figure 7B&C). Again, this beneficial effect of FA treatment was independent of GTPCH1 activity and intracellular 5'-MTHF level (Figs. 7D-F). These data seem to suggest that the beneficial effects of FA on vascular NO[•] bioavailability in Ang II infused mice are mediated by an upregulation of DHFR function.

DISCUSSION

The most significant finding of the study is that folic acid (FA) directly improves H₄B and NO[•] bioavailability while reducing oxidant production both *in vitro* and *vivo*, and that these effects are mediated by an upregulation of dihydrofolate reductase (DHFR) expression and activity. FA treatment of control or Ang II stimulated endothelial cells increased NO[•] production, which was attenuated by DHFR siRNA or methotrexate. In Ang II-infused mice, aortic O₂^{•-} production was attenuated by FA administration, whereas NO[•] levels were elevated. Endothelial expression of DHFR was markedly increased by FA, which is corresponding to a similar increase in activity.

As shown in Fig. 1, FA upregulates DHFR expression and NO[•] production in healthy endothelial cells at baseline. This seems consistent to what we found earlier that endogenous DHFR function is important for basal NO[•] production [23]. It is thus interesting to speculate that a deficiency in FA, i. e. caused by low dietary supplementation, may induce a DHFR deficiency that predisposes to vascular diseases. In consequent efforts to establish a sensitive and reliable HPLC-based activity assay for DHFR, FA was compared to dihydrofolic acid for substrate capability and found a second titer substrate with much less efficiency (K_m 7-fold higher, V_{max} 50-fold less). Nonetheless, it seems to implicate that when FA dietary supplementation is sufficient, DHFR activity would be important for its metabolism. Indeed, data from the Framingham Offspring Study demonstrated that a 19-bp polymorphism at intron 1 of DHFR gene is associated with increased plasma unmetabolized FA and decreased red blood cells folates [32].

Importantly, we developed a novel and sensitive HPLC-fluorescent based assay to measure DHFR activity. Using cell or tissue lysates, an optimal condition has been selected for maximal detection sensitivity: substrate dihydrofolate at 50 μmol/L, electron donor NADPH at 200 μmol/L, incubation for 20 min at 37°C, in a 0.1 mol/L potassium phosphate assay buffer (pH 7.4). The stabilization buffer maintains product (tetrahydrofolate, THF) stability at least

overnight at 4°C to allow autosampling performance. The HPLC-coupled electronic detection (ECD) method developed by Aiso et al [33] has similar sensitivity limit to our assay; but is associated with disadvantages such as handling of radioactivity, cost consumption, and complexity of the assay procedure. DHFR activity has been assayed at various pH and/or ambient temperature ranging from 21 to 28°C [34,35]. In this study, however, we assayed it at pH 7.4 and 37°C, which is more physiologically relevant. When dihydrofolic acid was used as a substrate, the reaction was not affected by pH (Fig. 3E), but significantly more sensitive at 37°C than at ambient temperature. Moreover, the product THF was stable in our assay system even after twenty min incubation at 37°C, and with the proper stabilizing buffer, can be analyzed by autosampler at 4°C overnight.

Elevated angiotensin II (Ang II) levels have been observed in many cardiovascular disorders where endothelial dysfunction occurs [36]. It is an independent risk factor for atherosclerosis and its antagonists have been used clinically to treat patients with hypertension. Thus it would be a good model system to test the effects of FA on endothelial function, which has already been implicated in coronary patients [22,37,38] and patients with hyperhomocysteinemia [39,40]. As expected, Ang II stimulation led to increased $O_2^{\bullet-}$ production and decreased $NO^{\bullet}$ and H_4B bioavailability. These responses were however all reversed significantly by FA pre-treatment. In addition, DHFR expression and activity were increased by FA. Pre-inhibition of DHFR by RNA interference or Methotrexate effectively abolished the beneficial effects of FA on endothelial cell functions. Besides these clear-cutting *in-vitro* observations, data collected from Ang II-infused mice also supported a strong impact of FA and an intermediate role of DHFR.

Mice infused with Ang II had markedly increased $O_2^{\bullet-}$ production and reduced $NO^{\bullet}$ bioavailability. This was accompanied by an endothelial downregulation of DHFR. Oral administration of FA significantly improved $NO^{\bullet}$ production, while reducing $O_2^{\bullet-}$ levels. It also reserved DHFR protein abundance from being diminished by Ang II. Changes in DHFR activity mirrored expressional regulations by Ang II and FA. Taken together, these data demonstrate that FA exerts its beneficial effects *in vivo* via regulation of DHFR expression and activity. It is important to note that in the endothelium-denuded aortas DHFR expression was upregulated by Ang II, indicating differential regulation of DHFR in different cell types. This seems logic as Ang II is known to stimulate vascular smooth muscle hypertrophy, and that DHFR in general is important for DNA synthesis and cell growth.

In summary, new data presented in the present study for the first time established that FA, via modulation of DHFR expression and activity, improves $NO^{\bullet}$ bioavailability while reducing $O_2^{\bullet-}$ production under pathophysiological conditions. These findings may represent a common mechanism whereby FA supplementation exerts beneficial effects on cardiovascular system in populations with and without hyperhomocysteinemia.

Acknowledgments

The authors' work has been supported by National Heart, Lung and Blood Institute (NHLBI) Grant HL077440 (HC), HL057244 (PLL and HC), HL080111 (PPP and HC), an American Diabetes Association Award 7-08-RA-23 (HC), and a Start-up Fund from the University of California Los Angeles (HC).

REFERENCES

1. Chivu CM, Tulchinsky TH, Soares-Weiser K, Braunstein R, Brezis M. A systematic review of interventions to increase awareness, knowledge, and folic acid consumption before and during pregnancy. *Am J Health Promot* 2008;22:237–245. [PubMed: 18421888]

2. Taparia S, Gelineau-van Waes J, Rosenquist TH, Finnell RH. Importance of folate-homocysteine homeostasis during early embryonic development. *Clin Chem Lab Med* 2007;45:1717–1727. [PubMed: 18067451]
3. Maron BA, Loscalzo J. The Treatment of Hyperhomocysteinemia. *Annu Rev Med.* 2008
4. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. *Am J Pathol* 1969;56:111–128. [PubMed: 5792556]
5. McCully KS. Homocysteine, vitamins, and vascular disease prevention. *Am J Clin Nutr* 2007;86:1563S–1568S. [PubMed: 17991676]
6. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med* 1998;338:1042–1050. [PubMed: 9535670]
7. Loscalzo J. Key references: Homocysteine and atherothrombotic vascular disease. *J Thromb Thrombolysis* 2000;9:125–126. [PubMed: 10590207]
8. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. *Arterioscler Thromb Vasc Biol* 2001;21:2080–2085. [PubMed: 11742888]
9. Wilcken B, Turner B. Homocystinuria. Reduced folate levels during pyridoxine treatment. *Arch Dis Child* 1973;48:58–62. [PubMed: 4685596]
10. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. *J Clin Invest* 1976;57:1079–1082. [PubMed: 947949]
11. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. *Arterioscler Thromb Vasc Biol* 2002;22:34–41. [PubMed: 11788458]
12. Weiss N, Heydrick SJ, Postea O, Keller C, Keaney JF Jr, Loscalzo J. Influence of hyperhomocysteinemia on the cellular redox state--impact on homocysteine-induced endothelial dysfunction. *Clin Chem Lab Med* 2003;41:1455–1461. [PubMed: 14656025]
13. Loscalzo J. Homocysteine trials--clear outcomes for complex reasons. *N Engl J Med* 2006;354:1629–1632. [PubMed: 16531615]
14. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. *Jama* 2007;298:1163–1170. [PubMed: 17848650]
15. Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. *Ann Intern Med* 2007;146:761–767. [PubMed: 17470822]
16. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. *Stroke* 2005;36:2404–2409. [PubMed: 16239629]
17. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med* 2006;354:1567–1577. [PubMed: 16531613]
18. Baigent C, Clarke R. B vitamins for the prevention of vascular disease: insufficient evidence to justify treatment. *Jama* 2007;298:1212–1214. [PubMed: 17848657]
19. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. *Lancet* 2007;369:1876–1882. [PubMed: 17544768]
20. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. *Jama* 2006;296:2720–2726. [PubMed: 17164458]
21. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. *Bmj* 2006;333:1114–1117. [PubMed: 17124224]
22. Moens AL, Vrints CJ, Claeys MJ, Timmermans JP, Champion HC, Kass DA. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. *Am J Physiol Heart Circ Physiol* 2008;294:H1971–H1977. [PubMed: 18375715]
23. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. *Proc Natl Acad Sci U S A* 2005;102:9056–9061. [PubMed: 15941833]

24. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. *Circ Res* 2000;87:840–844. [PubMed: 11073878]
25. Oak JH, Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. *Diabetes* 2007;56:118–126. [PubMed: 17192473]
26. Seujiang Y, Eiam-Ong S, Tirawatnapong T. Role of angiotensin II on dihydrofolate reductase, GTP-cyclohydrolase 1 and nitric oxide synthase expressions in renal ischemia-reperfusion. *Am J Nephrol* 2008;28:692–700. [PubMed: 18408363]
27. Ren J, Li H, Prior BM, Yang HT. Angiotensin converting enzyme inhibition enhances collateral artery remodeling in rats with femoral artery occlusion. *Am J Med Sci* 2008;335:177–187. [PubMed: 18344690]
28. Gao L, Pung YF, Zhang J, Chen P, Wang T, Li M, et al. Sepiapterin reductase regulation of endothelial tetrahydrobiopterin and nitric oxide bioavailability. *Am J Physiol Heart Circ Physiol* 2009;297:H331–H339. [PubMed: 19429835]
29. Bauer M, Suppmann S, Meyer M, Hesslinger C, Gasser T, Widmer HR, et al. Glial cell line-derived neurotrophic factor up-regulates GTP-cyclohydrolase I activity and tetrahydrobiopterin levels in primary dopaminergic neurones. *J Neurochem* 2002;82:1300–1310. [PubMed: 12358777]
30. Lu W, Li H, Zhang Y, Ang CY. Rapid method for the determination of total 5-methyltetrahydrofolate in blood by liquid chromatography with fluorescence detection. *J Chromatogr B Analyt Technol Biomed Life Sci* 2002;766:331–337.
31. Antoniadou C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. *Circulation* 2006;114:1193–1201. [PubMed: 16940192]
32. Kalmbach RD, Choumenkovitch SF, Troen AP, Jacques PF, D'Agostino R, Selhub J. A 19-base pair deletion polymorphism in dihydrofolate reductase is associated with increased unmetabolized folic acid in plasma and decreased red blood cell folate. *J Nutr* 2008;138:2323–2327. [PubMed: 19022952]
33. Aiso K, Nozaki T, Shimoda M, Kokue E. Assay of dihydrofolate reductase activity by monitoring tetrahydrofolate using high-performance liquid chromatography with electrochemical detection. *Anal Biochem* 1999;272:143–148. [PubMed: 10415082]
34. Kaufman BT, Kemerer VF. Purification and characterization of beef liver dihydrofolate reductase. *Arch Biochem Biophys* 1976;172:289–300. [PubMed: 1252081]
35. Webber S, Whiteley JM. Comparative activity of rat liver dihydrofolate reductase with 7,8-dihydrofolate and other 7,8-dihydropteridines. *Arch Biochem Biophys* 1985;236:681–690. [PubMed: 3970530]
36. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. *Trends Pharmacol Sci* 2003;24:471–478. [PubMed: 12967772]
37. Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? *Arterioscler Thromb Vasc Biol* 2001;21:1196–1202. [PubMed: 11451751]
38. Shirodaria C, Antoniadou C, Lee J, Jackson CE, Robson MD, Francis JM, et al. Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. *Circulation* 2007;115:2262–2270. [PubMed: 17420345]
39. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. *Circulation* 2000;102:2479–2483. [PubMed: 11076820]
40. Bellamy MF, McDowell IF, Lewis MJ. Folic acid in endothelial function in familial hypercholesterolemia. *Circulation* 2000;102:E92. [PubMed: 10982559]

Figure 1. Effects of folic acid on endothelial DHFR expression and NO^{*} production

A) Representative Western blot of on DHFR expression in FA (50 μ mol/L, 24h)-treated endothelial cells; B) Densitometric analysis of the immunoblots from A; C) Representative spectra of NO^{*} production in FA (50 μ mol/L, 24h)-treated endothelial cells; D) Grouped densitometric data of NO^{*} production. * p < 0.05 vs. Ctrl.

Figure 2. Specific tetrahydrofolate (THF) peak in the HPLC based DHFR activity assay

A) 50 nmol/L of tetrahydrofolate in assay buffer; B) 50 μ mol/L of dihydrofolate in assay buffer (no enzyme and NADPH); C) recombinant DHFR with 50 μ mol/L of dihydrofolate in assay buffer (no NADPH); D) boiled recombinant DHFR with 50 μ mol/L of dihydrofolate and 200 μ mol/L of NADPH in assay buffer (deactivated enzyme); E) recombinant DHFR with 200 μ mol/L of NADPH in assay buffer (no substrate); F) recombinant DHFR with 50 μ mol/L of dihydrofolate and 200 μ mol/L of NADPH in assay buffer; G) Sample constituents.

Figure 3. Optimization of the assay reaction for DHFR activity

DHFR activity is expressed as amount of tetrahydrofolate (THF) produced after 20 min incubation with 200 μmol/L NADPH, 500 ng/ml of recombinant DHFR and 80 μmol/L of dihydrofolic acid at pH 7.4. A) The THF production was examined after 2, 4, 6, 8, 10, 12, 16 and 20 min incubation while the rest of the assay condition remained the same as above; B) THF production was examined at different concentrations of NADPH; C) THF production was examined at different concentrations of recombinant DHFR; D) THF production was examined at different protein concentration of bovine endothelial cell lysates; E) THF production was examined at different pH; F) K_m and V_{max} of recombinant DHFR from the optimized assay reaction were calculated using Program Hyper 22 for hyperbolic regression analysis of enzyme kinetic data (<http://homepage.ntlworld.com/john.easterby/software.html>).

Figure 4. Effects of folic acid pre-incubation on Ang II induced changes in NO $\bullet$, H₄B availability and DHFR expression/activity

A) Effect of FA on Ang II induced changes in DHFR expression; B) Effect of FA on Ang II induced changes in DHFR activity; C) Effect of FA on Ang II induced changes in H₄B bioavailability; D) Effects of FA on the ratio of oxidized biopterins over total pterins; E) Effects of FA on Ang II induced NO $\bullet$ production. $p < 0.05$ vs. control, # $p < 0.05$ vs. Ang II alone.

Figure 5. Effect of DHFR inhibition on folic acid induced NO $\bullet$ production

A) DHFR siRNA on FA-induced DHFR-upregulation; B) DHFR siRNA on FA induced NO $\bullet$ production; C) Methotrexate on FA induced NO $\bullet$ production; D) FA treatment on GTPCH1 mRNA expression; E) FA treatment on GTPCH1 activity; F) FA treatment on intracellular 5'-MTHF level. * p < 0.05 vs. control, # p < 0.05 vs. AngII alone.

Figure 6. Effect of oral folic acid supplementation on aortic $\text{NO}^\bullet$ and $\text{O}_2^{\bullet-}$ production in Ang II-infused mice

A) Kinetic assay of aortic superoxide ($\text{O}_2^{\bullet-}$) production in AngII infused mice with or without FA supplementation; B) Group analysis of aortic $\text{O}_2^{\bullet-}$ production from A; C) Representative spectra of $\text{NO}^\bullet$ production in Ang II infused mice with or without FA supplementation; D) Group analysis of $\text{NO}^\bullet$ production from C. * $p < 0.05$ vs. control; # $p < 0.05$ vs. AngII alone.

Figure 7. Endothelium regulation of DHFR expression and activity by Ang II and folic acid in Ang II infused mice

A) Differential expression profile of DHFR in endothelium-denuded aortas and endothelial cells of untreated and Ang II infused mice; B) Effects of FA on endothelium regulation of DHFR expression in Ang II infused mice; C) Grouped densitometric data of B; D) Effects of FA on endothelium regulation of DHFR activity E) FA diet on endothelium GTPCH1 activity; F) FA diet on endothelium 5'-MTHF level. * $p < 0.05$ vs. control; # $p < 0.05$ vs. AngII alone.

Table 1

Recovery of tetrahydrofolate in assay buffer with cell lysates

Concentration (nmol/L)	Recovery (mean $\pm$ S.D.)	R.S.D. (%)
30	95.4 $\pm$ 1.8	1.9
50	96.1 $\pm$ 2.8	2.9
75	98.4 $\pm$ 1.8	1.8

Table 2

Intra- and Inter-day precision and accuracy of tetrahydrofolate in assay buffer

Concentration (nmol/L)	Inter-day precision (n=9)		Intra-day precision (n=3)	
	R.S.D. (%)	RE (%)	R.S.D. (%)	RE (%)
30	5.4	-3.2	3.5	-1.8
50	1.9	0.9	0.8	2.5
75	2.5	-1.5	2.5	-2.0